Figure 5 | Scientific Reports

Figure 5

From: Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties

Figure 5

VEGF binding properties of aflibercept. Binding of titrated amounts (1000.0–0.5 ng/ml) of aflibercept to VEGF165 at (A) D0 and D7, and (B) D0 and D28 in ELISA. (C) Comparison of aflibercept (37 nM) binding to VEGF165 at D0 and D7, and (D) at D0 and D28. Unpaired Student’s t-test was used for statistical calculations.

Back to article page